Analysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF), ACADIA Pharmaceuticals (ACAD) and Chemomab Therapeutics (CMMB)
TipRanksMay 6 07:50 ET
Chemomab Therapeutics Analyst Ratings
BenzingaMay 6 07:50 ET
Chemomab Therapeutics Analyst Ratings
BenzingaMar 8 08:45 ET
Roth MKM Reinstates Buy on Chemomab Therapeutics, Maintains $7 Price Target
BenzingaDec 19, 2023 09:14 ET
Chemomab Therapeutics Analyst Ratings
BenzingaDec 19, 2023 09:13 ET
Oppenheimer Reaffirms Their Hold Rating on Chemomab Therapeutics (CMMB)
TipRanksNov 10, 2023 10:06 ET
Roth MKM Initiates Coverage On Chemomab Therapeutics With Buy Rating, Announces Price Target of $7
BenzingaOct 6, 2023 08:56 ET
Chemomab Therapeutics Analyst Ratings
BenzingaOct 6, 2023 08:55 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Veralto Corporation (VLTO) and Chemomab Therapeutics (CMMB)
TipRanksOct 6, 2023 05:01 ET
Oppenheimer Adjusts Chemomab Therapeutics Price Target to $7 From $12, Maintains Outperform Rating
MT NewswiresApr 18, 2023 08:19 ET
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Lowers Price Target to $7
BenzingaApr 18, 2023 07:12 ET
No Data
No Data